Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response - report from ASH2023

Professor Mazyar Shadman on the findings from a real-world, retrospective study that were presented during the 2023 ASH Annual Meeting: Autologous hematopoietic cell transplantation lowered relapse and progression rates and improved survival outcomes vs CAR T-cell therapy in patients with relapsed large B-cell lymphoma who experienced complete remission with interim treatment. Video: https://medicaldigest.org/scientific-contents/interview:auto-hct-improves-pfs-relapse-rates-relapsed-lbcl-subset-during-complete-response